CSH2 (Complement System Homolog 2): A Potential Drug Target and Biomarker

Target Name: CSH2

NCBI ID: G1443

CSH2

CSH2 (Complement System Homolog 2): A Potential Drug Target and Biomarker

Introduction

The complement system is a crucial part of the immune system, which defends the body against external pathogens and helps maintain tissue health. Complement proteins, such as CSH2 (Complement System Homolog 2), play a vital role in this process. CSH2 is a 21 -kDa protein that is part of the complement system's third component, the C3b fraction. This protein is involved in the formation of the C3bb complex, which is responsible for activating and activating again the complement component C5 convertase (C5 convertase) to form C5b678, which is the final step in the complement cascade.

CSH2 is a potential drug target and biomarker due to its unique structure and function. Its potential drug targets include cancer, neurodegenerative diseases, and autoimmune disorders. The high expression level of CSH2 in various tissues and its involvement in the complement system make it an attractive target for researchers to study.

Drug Targets

CSH2 has been identified as a potential drug target for various diseases. Its involvement in the complement system makes it a potential target for cancer, neurodegenerative diseases, and autoimmune disorders.

1.Cancer

CSH2 has been shown to be involved in the regulation of the immune response and has been linked to cancer development. Studies have shown that CSH2 can suppress the immune response and promote the growth and survival of cancer cells. Therefore, targeting CSH2 could be an effective way to treat cancer.

2. Neurodegenerative Diseases

CSH2 has also been linked to the development and progression of neurodegenerative diseases. Its involvement in the complement system has been shown to contribute to the pathogenesis of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Therefore, targeting CSH2 could be an effective way to develop new treatments for neurodegenerative diseases.

3.Autoimmune Disorders

CSH2 has also been implicated in the development and maintenance of autoimmune disorders. Its involvement in the complement system has been shown to contribute to the development of autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis. Therefore, targeting CSH2 could be an effective way to develop new treatments for autoimmune disorders.

Biomarkers

CSH2 has also been identified as a potential biomarker for various diseases. Its unique structure and function make it an attractive target for researchers to study.

1.Cancer

Studies have shown that CSH2 can be used as a potential biomarker for cancer. Its expression level has been shown to be elevated in various types of cancer, including breast, lung, and ovarian cancer. Therefore, measuring the expression level of CSH2 could be an effective way to diagnose and monitor the progress of cancer.

2. Neurodegenerative Diseases

CSH2 has also been used as a potential biomarker for neurodegenerative diseases. Its expression level has been shown to be elevated in various types of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Therefore, measuring the expression level of CSH2 could be an effective way to diagnose and monitor the progression of neurodegenerative diseases.

3.Autoimmune Disorders

CSH2 has also been used as a potential biomarker for autoimmune disorders. Its expression level has been shown to be elevated in various types of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. Therefore, measuring the expression level of CSH2 could be an Effective way to diagnose and monitor the progression of autoimmune disorders.

Conclusion

In conclusion, CSH2 is a protein that plays a vital role in the complement system and has been

Protein Name: Chorionic Somatomammotropin Hormone 2

The "CSH2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CSH2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets